NCT00511654View on ClinicalTrials.gov

28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2007

Primary Completion Date

January 11, 2008

Study Completion Date

January 11, 2008

Conditions

Depressive Disorder

Interventions

DRUG

GW823296 tablet

GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.

DRUG

GW823296 matching placebo

Matching placebo tablets will be identical in appearance to the GW823296 tablets.

DRUG

Midazolam

Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).

Trial Locations (1)

14050

GSK Investigational Site, Berlin